| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/24/2011 | US20110070167 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| 03/24/2011 | US20110070162 Rna interference mediating small rna molecules |
| 03/24/2011 | US20110070155 Anti-CD74 Immunoconjugates and Methods |
| 03/24/2011 | US20110070154 Artificial cells |
| 03/24/2011 | US20110070153 Artificial cells |
| 03/24/2011 | CA2774796A1 Contact lens disinfecting solutions |
| 03/24/2011 | CA2774669A1 Oxaliplatin nanoparticles and method for preparing same |
| 03/24/2011 | CA2774645A1 Pharmaceutical composition for peroral administration of 3,3'-diindolylmethane |
| 03/24/2011 | CA2774556A1 Stabilized liquid and lyophilized adamts13 formulations |
| 03/24/2011 | CA2774495A1 Implant devices that differ by release profile and methods of making and using same |
| 03/24/2011 | CA2774356A1 Combination and composition that contains an antimicrobial, a glucocorticoid and an antimycotic |
| 03/24/2011 | CA2774269A1 Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency |
| 03/24/2011 | CA2774264A1 Improved device and method for delivery of a medicament |
| 03/24/2011 | CA2774210A1 Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| 03/24/2011 | CA2774168A1 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
| 03/24/2011 | CA2774053A1 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| 03/24/2011 | CA2773597A1 Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
| 03/24/2011 | CA2773596A1 Modified erythropoietin to which water-soluble long-chain molecule is added |
| 03/24/2011 | CA2773521A1 Oral pharmaceutical compositions comprising amine-containing compounds |
| 03/24/2011 | CA2773003A1 Orally disintegrating pharmaceutical dosage form containing aripiprazole |
| 03/24/2011 | CA2772965A1 Medical use of spla2 hydrolysable liposomes |
| 03/24/2011 | CA2772275A1 (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
| 03/24/2011 | CA2715242A1 Crosslinked polysiloxanes, a process for their preparation and use of the crosslinked polysiloxanes in emulsifier systems for water-in-oil emulsions |
| 03/23/2011 | EP2298829A1 Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| 03/23/2011 | EP2298728A1 Transfection reagents |
| 03/23/2011 | EP2298416A2 Sustained-release tramadol formulations with 24-hour clinical efficacy |
| 03/23/2011 | EP2298358A1 Methods for delivery of nucleic acids |
| 03/23/2011 | EP2298353A1 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 03/23/2011 | EP2298352A1 Percutaneous absorption enhancer and transdermal preparation using the same |
| 03/23/2011 | EP2298351A2 Therapeutic antimicrobial compositions and methods |
| 03/23/2011 | EP2298327A1 Anti-tumor agent |
| 03/23/2011 | EP2298324A1 Methods of increasing oral bioavailability of tetracyclines |
| 03/23/2011 | EP2298319A1 Device and methods for treating paranasal sinus conditions |
| 03/23/2011 | EP2298318A1 Device and methods for treating paranasal sinus conditions |
| 03/23/2011 | EP2298317A1 Device and methods for treating paranasal sinus conditions |
| 03/23/2011 | EP2298313A1 Pharmaceutical composition for external application containing prochlorperazine |
| 03/23/2011 | EP2298303A1 Pharmaceutical combinations of hydrocodone and naltrexone |
| 03/23/2011 | EP2298302A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 03/23/2011 | EP2298298A2 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
| 03/23/2011 | EP2298294A1 Oxybuprocaine-containing analgesic/antipruritic preparation for external application |
| 03/23/2011 | EP2298290A1 Controlled release composition comprising levetiracetam |
| 03/23/2011 | EP2298289A1 Dosage form with time-lagged release of zaleplon for the therapy of insomnia |
| 03/23/2011 | EP2298288A1 Coated tablet formulation and method |
| 03/23/2011 | EP2298287A2 Stabilised compositions of factor VII polypeptides |
| 03/23/2011 | EP2298286A1 Process for dewatering of product powders and pharmaceutical compositions produced according to this process |
| 03/23/2011 | EP2298285A2 Method of making particles for use in a pharmaceutical composition |
| 03/23/2011 | EP2298284A2 Mucoadhesive pharmaceutical formulations |
| 03/23/2011 | EP2298283A2 Pharmaceutical formulations comprising cannabinoids |
| 03/23/2011 | EP2298282A1 Combination of drugs having different physical properties into single dosage form |
| 03/23/2011 | EP2298281A1 Infusion and injection solution of Levodopa |
| 03/23/2011 | EP2298280A2 Gel comprising a combination of flurbiprofen and muscle relaxant |
| 03/23/2011 | EP2298279A2 Pharmaceutical compositions for inhalation |
| 03/23/2011 | EP2298278A1 Prevention and reduction of blood loss |
| 03/23/2011 | EP2298277A1 Transdermal patch formulation |
| 03/23/2011 | EP2298276A1 Accelerating agent of calcium absorption |
| 03/23/2011 | EP2297172A2 Process for producing nanoparticles |
| 03/23/2011 | EP2296772A1 Amphiphilic proteins as morphology modifiers |
| 03/23/2011 | EP2296748A1 Ketotifen transdermal drug delivery systems and methods for treating ophthalmic disease |
| 03/23/2011 | EP2296710A1 Modified protein excipient for delayed-release tablet |
| 03/23/2011 | EP2296709A2 Modified release niacin formulations |
| 03/23/2011 | EP2296696A1 Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| 03/23/2011 | EP2296695A1 Nanoparticles containing proteolytic enzymes for the treatment of peyronie's disease |
| 03/23/2011 | EP2296652A1 Topical regional neuro-affective therapy |
| 03/23/2011 | EP2296637A1 Chitosan-containing protective composition |
| 03/23/2011 | EP2296636A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
| 03/23/2011 | EP2296635A2 Artificial oxygen carriers and use thereof |
| 03/23/2011 | EP2296634A1 Process for manufacture of a medicament with granulation and pan coating |
| 03/23/2011 | EP2296633A2 The use of solid carrier particles to improve the processability of a pharmaceutical agent |
| 03/23/2011 | EP2296632A2 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| 03/23/2011 | EP2296631A1 Method for manufacturing medicinal compounds containing dabigatran |
| 03/23/2011 | EP2296630A2 Delivery of nucleic acid complexes from particles |
| 03/23/2011 | EP2296629A2 Biocompatible and biodegradable elastomeric polymers |
| 03/23/2011 | EP2296628A2 Process for manufacturing flowable powder drug compositions |
| 03/23/2011 | EP2296627A2 Micelles for intracellular delivery of therapeutic agents |
| 03/23/2011 | EP2296626A1 Azide modified proteins |
| 03/23/2011 | EP2296625A1 Pharmaceutical formulation of ketorolac for intranasal administration |
| 03/23/2011 | EP2296624A1 New emulsions for producing medicinal products |
| 03/23/2011 | EP2296623A1 Compositions for the treatment of lice |
| 03/23/2011 | EP2296622A2 Electronic pill comprising a medicine reservoir |
| 03/23/2011 | EP2296621A1 Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| 03/23/2011 | EP2296620A2 Magnetic microbubbles, methods of preparing them and their uses |
| 03/23/2011 | EP2296597A1 Polyamine enhanced formulations for triptan compound iontophoresis |
| 03/23/2011 | EP2296490A1 Process for manufacturing chewing gum having a coating layer, and the chewing gum obtainable by said process |
| 03/23/2011 | EP2296486A1 Film-coated compressed chewing gum |
| 03/23/2011 | EP2296470A2 Compositions and methods for inhibiting gastric acid secretion |
| 03/23/2011 | EP2136785B1 Process for dosing self-emulsifying drug delivery systems |
| 03/23/2011 | EP2015736B1 Spherical or non-sperical microcapsules comprising glp-1 peptides, their production and use |
| 03/23/2011 | EP1811978B1 Production of double- or multi-layered microcapsules |
| 03/23/2011 | EP1691844B1 Methods and compositions for treatment of interferon-resistant tumors |
| 03/23/2011 | EP1552821B1 Liner for sticking plaster |
| 03/23/2011 | EP1515741B1 Use of collagen hydrolysate to lower the viscosity of a composition comprising guar gum |
| 03/23/2011 | EP1446101B1 Catheter injectable depot compositions and uses thereof |
| 03/23/2011 | EP1441784B1 Medical device for delivering patches |
| 03/23/2011 | EP1390084B1 Two-phase, water-absorbent bioadhesive composition |
| 03/23/2011 | EP1353647B1 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
| 03/23/2011 | EP1320386B1 A novel cationic lipopolymer as biocompatible gene delivery agent |
| 03/23/2011 | EP1320377B1 Hla binding peptides and their uses |
| 03/23/2011 | EP1112739B1 Long time drug-sustained release preparation |
| 03/23/2011 | CN201768070U Medical hot patch |
| 03/23/2011 | CN1990032B Composite intravenous injection emulsion of glossy ganoderma spore oil and coix seed oil and method for making same |